CJC-1295 is a tetrasubstituted analog of GHRH designed to resist proteolytic degradation. The DAC form covalently binds to albumin after injection, dramatically extending its half-life to approximately one week in animal models.
Sequence
Modified GHRH(1–29) analog
Molecular Weight
~3,367 g/mol (DAC form)
Half-life (Preclinical)
~7–8 days (DAC form); ~30 min (without DAC)
Mechanism
GHRH receptor agonist; amplifies pulsatile GH secretion from somatotrophs
Storage
-20°C lyophilized
Solubility
Sterile water
Research Summary
CJC-1295 has been studied for its ability to produce sustained elevation of GH and IGF-1 levels in rodent and primate models. When combined with GHRPs, synergistic GH release is well-documented in animal research.
Research Strengths
Extended half-life (DAC form)
Well-studied in animal models
Predictable GHRH receptor activity
Useful for chronic protocols
Limitations & Considerations
Blunts natural pulsatility (DAC form)
Complex synthesis
Requires careful reconstitution
This information is for research reference only. CJC-1295 is a Research Use Only (RUO) compound not approved for human or veterinary use. This does not constitute medical advice.